EDMONTON, ALBERTA--(CCNMatthews - Dec. 12, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, announced that an abstract relating to pre-clinical data from a hepatitis C ChimigenTM vaccine candidate will be presented at the HepDART 2005: Frontiers in Drug Development for Viral Hepatitis in Hawaii. The conference is being held from December 11 to December 15 in the Kohala Coast, Hawaii at the Fairmont Orchid Hotel. Dr. Lorne Tyrrell, Chief Executive Officer and Dr. Rajan George, Vice President, Research and Development, Infectious Diseases at ViRexx Medical Corp. will be presenting an abstract entitled “A Novel Dendritic Cell-Targeted Chimeric Therapeutic Vaccine for the Treatment of Chronic C Infection”.
